Komori
Astellas Pharma (4503) · InitiativeAchieved

Discontinuation of ASP8062 development

First written in FY2023. 1 of 1 entries say "Achieved", first in FY2023. Latest entry: FY2023.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Discontinuation of ASP8062 development for opioid use disorderA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023AchievedAnnual report

    「2022年８月　GABA B受容体陽性アロステリック修飾物質ASP8062について、オピオイド使用障害を対象として臨床第Ⅱ相段階にあった開発を中止したことを公表しました。」

    ASP8062について、オピオイド使用障害を対象とする第Ⅱ相開発を中止した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.